Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
2-Step Matched Related HSCT with 5+5 Dosing for Hematological Malignancies
NCT03712878Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2018
- Primary completion
- Mar 2025
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donor lymphocytes and allogeneic hematopoietic stem cells in hematological malignancy, sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Percentage of Participants With Donor T Cell Chimerism Values Greater Than or Equal to 98% at Day 28. Started Sep 2018; status: completed.
02
Drugs
donor lymphocytesallogeneic hematopoietic stem cells
03
Conditions
hematological malignancy
Beyond the preview
Go deeper on NCT03712878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712878.